4359
haloarenes 6±7. These signi®cant, unusual features are the consequence of the intramolecular
nature of the reported reaction, as the high constraint generated in the corresponding oxidative
addition intermediate would be released by the otherwise dicult reductive elimination process.
The latter theory would also explain the lack of reactivity of pyrazole 6c, since the steric
hindrance induced by the methoxy (R7=OMe) and N-phenyl substituents could even avoid the
displacement of the halide ligand to form the corresponding octacyclic Ar±Pd±OAr0 complex.21
On the other hand, the comparison of the obtained results from the coupling of substrates 6d and
6e suggests that the presence of an electron-donating substituent ortho to the hydroxy group
might dicult the formation of the latter intermediate, probably due to the unstability of the
initially formed aryl palladium(II) halide, which is more remarkable in the case of iodide derivative
6d. This behaviour of aryl iodides for this type of transformation has been previously reported.11b
To sum up, a series of new dibenzoxepino[4,5-d]pyrazoles has been obtained by a convenient
palladium catalyzed C±O coupling reaction of o,o0-halohydroxysubstituted diarylpyrazoles. This
novel palladium catalyzed intramolecular diaryl ether formation has been carried out with two
dierent chelating ligands, aording moderate to good yields of the target tetracycles prepared by
coupling of phenoxides with non-activated arene and aryl iodide moieties.
We are currently investigating the expansion of the scope of the coupling conditions set up to
other diaryl heterocyclic systems, as well as trying to develop new palladium catalytic systems for
related transformations.
Acknowledgements
Financial support from the University of the Basque Country (Project UPV 170.310G37/98),
the Ministerio de Educacion y Cultura (PB97-0600), the Basque Government (GV170.310-
G0053/96) and a fellowship granted to R.O. are also gratefully acknowledged.
References
1. For a review see: (a) Nagai, Y.; Irie, A.; Nakamura, H.; Hino, K.; Uno, H.; Nishimura, H. J. Med. Chem. 1982,
25, 1065±1070. (b) Sperling, W.; Demling, J. Drugs Today 1997, 33, 95±102. (c) Claghorn, J.; Lesem, M. D. Prog.
Drug. Res. 1996, 46, 243±262.
2. (a) Bischho, S. In Novel Antipsychotic Drugs; Meltzer: New York, 1992; pp. 117±134. (b) Room, P.; Tielemans,
A. J. P. C.; de Boer, T.; Van Delft, A. M. L.; Jeroen, J. A. D. M. Eur. J. Pharmacol. 1991, 205, 233±240.
3. (a) Andree, B.; Halldin, C.; Vrijmoed, M.; Farde, L. Psycopharmacol. 1997, 113, 339±345. (b) Maduskuie, T. P.;
Wilde, R. G.; Billheimer, J.; Cromley, D. A.; Germain, S.; Gillies, P. J.; Higley, C. A.; Johnson, A. L.; Penner, P.
J. Med. Chem. 1995, 38, 1067±1083.
4. (a) Domõnguez, E.; Mtez. de Marigorta, E.; Olivera, R.; SanMartin, R. Synlett 1995, 955±956. (b) Domõnguez, E.;
Ibeas, E.; Mtez. de Marigorta, E.; Palacios, J. K.; SanMartin, R. J. Org. Chem. 1996, 61, 5435±5439.
5. (a) Olivera, R.; Pascual, S.; Herrero, M.; SanMartin, R.; Domõnguez, E. Tetrahedron Lett. 1998, 39, 7155±7158.
(b) Olivera, R.; SanMartin, R.; Pascual, S.; Herrero, M.; Domõnguez, E. Tetrahedron Lett. 1999, 40, 3479±3480.
6. (a) Hartwig, J. F. Acc. Chem. Res. 1998, 31, 852±860. (b) Hartwig, J. F.; Kawatsura, M.; Hauck, S. I.; Shaghnessy,
K. H.; Alcazar-Roman, L. M. J. Org. Chem. 1999, 64, 5575±5580.
7. (a) de la Fuente, M. C.; Castedo, L.; Domõnguez, D. Tetrahedron 1996, 52, 4917±4924. (b) Rossi, R; Bellina, F.;
Ciucci, D.; Carpita, A.; Fanelli, C. Tetrahedron 1998, 54, 7595±7614.
8. (a) Janetka, J. W.; Rich, D. H. J. Am. Chem. Soc. 1997, 119, 6485±6488. (b) Sawyer, J. S.; Schmittling, E. A.;
Palkowitz, J. A.; Smith, W. J. J. Org. Chem. 1998, 63, 6338±6343. (c) Boger, D. L.; Castle, S. L.; Miyazaki, S.; Wu,
J. H.; Beresis, R. T.; Loiseleur, O. J. Org. Chem, 1999, 64, 70±80.